The primary goal of the Administrative Services Core will be to provide the integration, administrative support and oversight necessary for the projects and cores to accomplish the overall specific aims of the Immunotherapeutics of Ovarian Cancer P01 as outlined by corresponding the 4 projects. The Administrative Core will be led by Dr. Spriggs.
The specific aims are: 1) To create synergy among the 4 projects and the cores; 2) To provide seamless budgetary oversight for the programs and cores; 3) To schedule and support the program meetings, as well as facilitate evaluation and communications among the projects; 4) To distribute and archive the publications, reports and grant elements from the components of the PO1; 5) To schedule, facilitate and manage the meetings of the executive committee, the internal advisory committee and the external advisory committee.

Public Health Relevance

The primary goal of the Administrative Services Core will be to provide the administrative support and oversight necessary for the projects and cores to accomplish the overall specific aims of the Immunotherapeutics of Ovarian Cancer P01 as outlined by corresponding the 4 projects. The Administrative Core will be led by Dr. Spriggs. The specific aims are: 1) To insure synergy among the 4 projects and 3 cores; 2)To provide seamless budgetary oversight for the programs and cores; 3) To schedule and support the program meetings, as well as facilitate evaluation and communications among the projects; 4) To distribute and archive the publications, reports and grant elements from the components of the PO1; 5) To schedule, facilitate and manage the meetings of the executive committee, the internal advisory committee and the external advisory committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA190174-01A1
Application #
8933337
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
2015-09-01
Project End
2020-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$82,874
Indirect Cost
$32,688
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Knorr, David A; Dahan, Rony; Ravetch, Jeffrey V (2018) Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A 115:11048-11053
Cornetta, Kenneth; Duffy, Lisa; Feldman, Steven A et al. (2018) Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Mol Ther Methods Clin Dev 10:371-378
Rafiq, Sarwish; Yeku, Oladapo O; Jackson, Hollie J et al. (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36:847-856
Bournazos, Stylianos; Ravetch, Jeffrey V (2017) Fc? Receptor Function and the Design of Vaccination Strategies. Immunity 47:224-233
Hectors, Stefanie J; Wagner, Mathilde; Bane, Octavia et al. (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep 7:2452
Yeku, Oladapo; Li, Xinghuo; Brentjens, Renier J (2017) Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book 37:193-204
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Rao, Thapi Dharma; Fernández-Tejada, Alberto; Axelrod, Abram et al. (2017) Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. ACS Chem Biol 12:2085-2096
Bournazos, Stylianos; Wang, Taia T; Dahan, Rony et al. (2017) Signaling by Antibodies: Recent Progress. Annu Rev Immunol 35:285-311

Showing the most recent 10 out of 22 publications